Abstract: KRAS is one of the best-known proto-oncogenes.Its gain-of-function mutations occur in approximately 30% of all human cancers and are commonly associated with poor prognosis and therapeutic resistance.Despite its well-recognized importance in cancer malignancy, no selective inhibitors have been approved for KRAS mutant cancer treatment.Recent studies have shown that KRAS mutation promotes a metabolic reprogramming of tumor cells to produce essential nutrients to support unconstrained proliferation, therefore, targeting metabolic reprogramming also provides a new direction for tumor therapy.This article reviews the latest metabolic reprogramming caused by KRAS mutation in tumors with a summary of related potential therapeutic targets.